Abstract
Tang et al. (1) reported that the administration of insulin glargine, but not liraglutide, reduced the liver fat burden in patients with type 2 diabetes, whereas the improvement in the liver fat fraction was not significantly different from that in the liraglutide group in a 12-week randomized trial. This is an interesting clinical study on the effects of antihyperglycemic drugs on liver fat. However, there are some concerns about this study. First, given the different mechanisms by which insulin glargine and liraglutide therapies may reduce liver fat, the short observation period of 12 weeks may not be long enough to show the actual effects of the two agents, especially for liraglutide. …
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
